Open access · US-GOV
via ClinicalTrials.gov Clinical trial
A Randomized Phase III Randomized Study to Compare R-CHOP Versus R-mini-CEOP in Elderly Patients (>65 Years) With Diffuse Large B Cell Lymphoma (DLBCL)
Authors not listed
Fondazione Italiana Linfomi - ETS · 2003
Abstract
The study has the purpose to compare R-CHOP versus R-mini-CEOP in elderly patients (\>65 years) with Diffuse Large B Cell Lymphoma (DLBCL).
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-11-01 MST
Cite this
APA
Anonymous. (2003). A Randomized Phase III Randomized Study to Compare R-CHOP Versus R-mini-CEOP in Elderly Patients (>65 Years) With Diffuse Large B Cell Lymphoma (DLBCL). <em>Fondazione Italiana Linfomi - ETS</em>. https://clinicaltrials.gov/study/NCT01148446
Vancouver
Anonymous. A Randomized Phase III Randomized Study to Compare R-CHOP Versus R-mini-CEOP in Elderly Patients (>65 Years) With Diffuse Large B Cell Lymphoma (DLBCL). Fondazione Italiana Linfomi - ETS. 2003.
BibTeX
@misc{anon2003ARando,
title = {A Randomized Phase III Randomized Study to Compare R-CHOP Versus R-mini-CEOP in Elderly Patients (>65 Years) With Diffuse Large B Cell Lymphoma (DLBCL)},
author = {Anonymous},
journal = {Fondazione Italiana Linfomi - ETS},
year = {2003},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
The First Affiliated Hospital with Nanjing Medical University 2016
Open access · US-GOV
Phase III,Randomized Controlled Trial of R-GemOx Versus R-miniCHOP Regimen in First-line Treatment of Elderly Diffuse Large B Cell Lymphoma
Guangdong Provincial People's Hospital 2020
Open access · US-GOV
Lenalidomide Combined With Rituximab as Front-line Therapy in Elderly Patients Aged Over 80 Years With Diffuse Large B Cell Lymphoma
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea 2013
Open access · US-GOV
Phase II, Randomised, Multicentre Study With Two Treatment Arms (R-COMP Versus R-CHOP) in Newly Diagnosed Elderly Patients (≥60 Years) With Non-localised Diffuse Large B-cell Lymphoma (DLBCL)/Follicular Lymphoma Grade IIIb.
First Affiliated Hospital of Wenzhou Medical University 2022
Open access · US-GOV
The Efficacy and Safety of ZR2 Versus R-CHOP-like Regimen for Elderly Patients With Newly Diagnosed Diffuse Large B Cell Lymphoma.
Lymphoma Study Association 2003
Open access · US-GOV
Randomized Study of ACVBP Versus ACVBP Plus Rituximab in Previously Untreated Patients Aged From 18 to 65 Years With Low-risk Localized Diffuse Large B-cell Lymphoma (Age-adjusted IPI = 0)
The First Affiliated Hospital with Nanjing Medical University 2020
Open access · US-GOV